BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH), subsequent to pulmonary embolism is a relatively frequent cause of pulmonary hypertension. Similar to patients with pulmonary arterial hypertension (PAH), CTEPH carries a poor prognosis. There is no hard evidence for any other therapy except pulmonary endarterectomy and none for those patients that are not eligible for this procedure. PATIENTS AND METHODS: Fifty patients with confirmed, inoperable CTEPH receiving specific vasodilative therapy (prostanoids, endothelin receptor antagonists, PDE 5-inhibitors or combination) were included in this retrospective study (mean age 55 years, range 16-76 years; 36 female, 14 male). Kaplan-Meier plots of these patients were compared with Kaplan-Meier plots of two historical CTEPH patient groups without any specific vasodilative treatment by log rank tests. RESULTS: CTEPH patients treated with specific vasodilative compounds as used for therapy of PAH were followed up for 52 +/- 30 months and had a significantly improved survival compared with patients treated without PAH type vasodilators (p < or = 0.0002). CONCLUSION: Our data may generate the hypothesis that specific vasodilative treatment improves outcome in patients with inoperable CTEPH.
BACKGROUND:Chronic thromboembolic pulmonary hypertension (CTEPH), subsequent to pulmonary embolism is a relatively frequent cause of pulmonary hypertension. Similar to patients with pulmonary arterial hypertension (PAH), CTEPH carries a poor prognosis. There is no hard evidence for any other therapy except pulmonary endarterectomy and none for those patients that are not eligible for this procedure. PATIENTS AND METHODS: Fifty patients with confirmed, inoperable CTEPH receiving specific vasodilative therapy (prostanoids, endothelin receptor antagonists, PDE 5-inhibitors or combination) were included in this retrospective study (mean age 55 years, range 16-76 years; 36 female, 14 male). Kaplan-Meier plots of these patients were compared with Kaplan-Meier plots of two historical CTEPHpatient groups without any specific vasodilative treatment by log rank tests. RESULTS:CTEPHpatients treated with specific vasodilative compounds as used for therapy of PAH were followed up for 52 +/- 30 months and had a significantly improved survival compared with patients treated without PAH type vasodilators (p < or = 0.0002). CONCLUSION: Our data may generate the hypothesis that specific vasodilative treatment improves outcome in patients with inoperable CTEPH.
Authors: O Sitbon; V V McLaughlin; D B Badesch; R J Barst; C Black; N Galiè; M Humbert; M Rainisio; L J Rubin; G Simonneau Journal: Thorax Date: 2005-07-29 Impact factor: 9.139
Authors: Ralf Ewert; Christian F Opitz; Roland Wensel; Jörg Winkler; Michael Halank; Stephan B Felix Journal: Clin Res Cardiol Date: 2007-02-15 Impact factor: 5.460
Authors: Horst Olschewski; M M Hoeper; M M Borst; R Ewert; E Grünig; F-X Kleber; B Kopp; C Opitz; F Reichenberger; A Schmeisser; D Schranz; I Schulze-Neick; H Wilkens; J Winkler; H Worth Journal: Clin Res Cardiol Date: 2007-05 Impact factor: 5.460
Authors: Hossein A Ghofrani; Ralph T Schermuly; Frank Rose; Ralph Wiedemann; Markus G Kohstall; André Kreckel; Horst Olschewski; Norbert Weissmann; Beate Enke; Stefanie Ghofrani; Werner Seeger; Friedrich Grimminger Journal: Am J Respir Crit Care Med Date: 2003-01-24 Impact factor: 21.405
Authors: Diana Bonderman; Regina Nowotny; Nika Skoro-Sajer; Johannes Jakowitsch; Christopher Adlbrecht; Walter Klepetko; Irene M Lang Journal: Chest Date: 2005-10 Impact factor: 9.410
Authors: R J Hughes; X Jais; D Bonderman; J Suntharalingam; M Humbert; I Lang; G Simonneau; J Pepke-Zaba Journal: Eur Respir J Date: 2006-04-12 Impact factor: 16.671
Authors: Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger Journal: N Engl J Med Date: 2002-08-01 Impact factor: 91.245
Authors: Hans-Jürgen Seyfarth; Stefan Hammerschmidt; Michael Halank; Petra Neuhaus; Hubert R Wirtz Journal: Pulm Circ Date: 2013-11-19 Impact factor: 3.017
Authors: Jochen Gille; Hans-Jürgen Seyfarth; Stefan Gerlach; Michael Malcharek; Elke Czeslick; Armin Sablotzki Journal: Anesthesiol Res Pract Date: 2012-10-12